Insider · CIK 0002118765
Jamie Beth Coleman
Files at KLRA (Kailera Therapeutics, Inc.). First filing -, latest -.
In brief
Jamie Beth Coleman files SEC Form 4 as officer at KLRA (Kailera Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jamie Beth Coleman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 20, 2026 |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 20, 2026 |
Questions about Jamie Beth Coleman
Answered from the filings on this page, as of the latest one.
Is Jamie Beth Coleman buying or selling?
Jamie Beth Coleman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jamie Beth Coleman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jamie Beth Coleman has 0.
Where does Jamie Beth Coleman file Form 4?
Jamie Beth Coleman has filed Form 4 at KLRA (Kailera Therapeutics, Inc.) as Chief Commercial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.